STOCK TITAN
  1. Home
  2. Sec-filings
  3. VNDA
  4. [8-K] Vanda Pharmaceuticals Inc. Reports Material Event

Vanda Pharmaceuticals (NASDAQ: VNDA) CEO outlines DTC channel for FDA-approved motion drug

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Vanda Pharmaceuticals Inc. reported that its President, Chief Executive Officer and Chairman, Dr. Mihael Polymeropoulos, appeared on Fox Business’ Mornings with Maria to discuss pricing and commercial plans for a drug recently approved by the U.S. Food and Drug Administration to prevent vomiting caused by motion.

During the interview, he stated that Vanda is developing a direct-to-consumer channel to provide access to this drug and indicated that the channel is expected to be available in the next couple of months. The company furnished a link to the full televised interview for reference.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Understanding 8-K Material Events →
0001347178FALSE00013471782026-03-102026-03-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 10, 2026
VANDA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
Delaware001-3418603-0491827
(State or other jurisdiction of incorporation)(Commission File No.)(IRS Employer Identification No.)
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (202) 734-3400
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareVNDAThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨


Item 7.01.Regulation FD Disclosure.
On March 10, 2026, Mihael Polymeropoulos, M.D., President, Chief Executive Officer and Chairman of the Board of Vanda Pharmaceuticals Inc. (“Vanda”), appeared on Mornings with Maria on Fox Business and discussed Vanda’s pricing and commercial strategy for its drug, NEREUSTM, which was recently approved by the U.S. Food and Drug Administration for the prevention of vomiting induced by motion. During the interview on Fox Business, Dr. Polymeropoulos disclosed that Vanda is developing NEREUSRXTM, which will be a direct-to-consumer channel for access to NEREUSTM. Dr. Polymeropoulos then indicated that NEREUSTM will be available in the next couple of months. The full interview can be seen here: https://www.foxbusiness.com/video/6390680373112.
The information furnished pursuant to this Item 7.01 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:March 10, 2026 VANDA PHARMACEUTICALS INC.
 By:/s/ Timothy Williams
 Name:Timothy Williams
 Title:Senior Vice President, General Counsel and Secretary

Source: View Original Filing on SEC EDGAR

FAQ

What did Vanda Pharmaceuticals (VNDA) disclose in its March 10, 2026 Form 8-K?

Vanda disclosed that its CEO, Dr. Mihael Polymeropoulos, appeared on Fox Business to discuss pricing and commercial strategy for a newly FDA-approved drug. The filing highlights this media appearance and summarizes key points from the discussion for investors and the market.

What drug did Vanda Pharmaceuticals (VNDA) discuss in the Fox Business interview?

The CEO discussed a Vanda drug recently approved by the U.S. Food and Drug Administration to prevent vomiting induced by motion. The conversation focused on its pricing, commercialization approach, and how Vanda plans to make it available to patients through future distribution channels.

What direct-to-consumer plan did Vanda (VNDA) describe in the Form 8-K?

Vanda reported that its CEO said the company is developing a direct-to-consumer channel to provide access to its newly approved motion-related vomiting prevention drug. He indicated this channel is expected to become available within the next couple of months, expanding how patients obtain the therapy.

How soon did Vanda (VNDA) say its direct-to-consumer channel could launch?

During the Fox Business interview, Vanda’s CEO indicated the new direct-to-consumer access channel for the FDA-approved drug should be available in the next couple of months. This timing suggests near-term commercial activity focused on reaching patients more directly outside traditional prescribing pathways.

Where can investors watch the Vanda (VNDA) CEO’s Fox Business interview?

Vanda provided a direct link to the full interview, hosted on Fox Business, in its Form 8-K. Viewers can access it at https://www.foxbusiness.com/video/6390680373112, which shows Dr. Mihael Polymeropoulos discussing pricing, commercialization, and direct-to-consumer plans for the approved motion-related drug.

Filing Exhibits & Attachments

3 documents

Other Documents